The behaviour of human vitronectin in vivo: Effects of complement activation, conformation and phosphorylation

Clinical and Experimental Immunology

Volumn 106, Issue 2, 1996, Pages 416-422

  Peake, P W ^a   Greenstein, J D ^a   Pussell, B A ^a   Charlesworth, J A ^a  

^a PRINCE HENRY HOSPITAL   (Australia)

Author keywords

human; metabolism; phosphorylation; vitronectin

Indexed keywords

COBROTOXIN; COMPLEMENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; VITRONECTIN;

ANIMAL EXPERIMENT; ARTICLE; COMPLEMENT ACTIVATION; HALF LIFE TIME; HUMAN; METABOLISM; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RABBIT; TISSUE DISTRIBUTION;

EID: 0029847859     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-833.x     Document Type: Article

References (30)

1. Preissner KT, Heimburger EA, Anders E, Muller-Berghaus G Physicochemical, immunochemical and functional comparison of human S-protein and vitronectin. Evidence for the identity of both plasma proteins. Biochem Biophys Res Commun 1986; 134:951 6.
2. Hayashi M. Vitronectins: from vertebrates to invertebrates. In: Preissner KT, Rosenblatt S, Kost C, Wegerhoff, Mosher D, eds. Biology of vitronectins and their receptors. Amsterdam: Elsevier. 1993;3 11.
3. Preissner KT, Jenne D. Structure of vitronectin and its biological role in haemostasis. Thromb Haemostasis 1991; 66:123 32.
4. Preissner KT, Muller-Berghaus G. Neutralization and binding of heparin by S protein vitronectin in the inhibition of Factor Xa by antithrombin III. Involvement of an inducible heparin binding domain of S protein/vitronectin. J Biol Chem 1987; 262:12247 53.
5. Hess S, Stockmann A, Volker W, Preissner KT. Multimeric vitronectin: structure and function. In: Preissner KT, Rosenblatt S, Kost C, Wegerhoff J, Mosher D, eds. Biology of vitronectins and their receptors. Amsterdam: Elsevier. 1993; 21 9.
6. Bale MD, Wohlfahrt LA, Mosher D, Tomasini B, Sutton RC. Identification of vitronectin as a major plasma protein absorbed on polymer surfaces of different copolymer composition. Blood 1989; 74:2698 706.
7. Yatohgo T, Izumi M, Kashiwagi H, Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct 1988; 13:281 92.
8. Volker W, Hess S, Vischer P, Preissner KT. Binding and processing of multimeric vitronectin by vascular endothelial cells. J Histochem. Cytochem. 1993; 41:1823-32.
9. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Muller-Berghaus G, Collen D. Purification and characterisation of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263:25454 61.
10. Lawrence DA, Naski MC, Berkenpas MB, Palaniappan S, Podor TJ, Mosher DF, Ginsburg D. The interaction of plasminogen activator inhibitor-1 with vitronectin. In: Preissner KT, Rosenblatt S, Kost C, Wegerhoff J, Mosher D, eds. Biology of vitronectins and their receptors. Amsterdam: Elsevier, 1993; 303-10.
11. Shaltiel S, Schvartz I, Gechtman Z, Kreizman T. Covalent modulation of vitronectin structure of the control of plasminogen activation by PAI-1. In. Preissner KT, Rosenblatt S, Kost C, Wegerhoff J, Mosher D, eds. Biology of vitronectins and their receptors. Amsterdam: Elsevier. 1993; 311 24.
12. Podack ER, Muller-Eberhard HJ. Isolation of human S-protein, an inhihbitor of the membrane attack complex of complement. J Biol Chem 1979; 254:9908 14.
13. Greenstein JD, Peake PW, Charlesworth JA. The kinetics and distribution of C9 and SC5b-9 in vivo: effects of complement activation. Clin Exp Immunol 1995; 100:40 6.
14. Bariety J, Hinglais N, Bhakdi S., Mandet C, Rouchon M, Kazatchkine M. Immunohistochemical study of complement S protein (vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 complex. Clin Exp. Immunol. 1989; 75:76 81.
15. Tschopp J, Masson D, Schafer S, Peitsch M, Preissner KT. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytie activities. Biochemistry 1988; 27:4103 9
16. McGuire EA, Peacock ME, Inhorn RC, Siegel NR, Tollefsen DM. Phosphorylation of vitronectin by a protein kinase in human plasma. Identification of a unique phosphorylation site in the heparin binding domain. J Biol Chem 1988; 263:1942 5.
17. Shaltiel, S., Schvartz I., Korc-Grodzicki B., and Kreizman T. Evidence for an extra-cellular function for protein kinase A. Mol Cell Bioehem 1993; 128:283 91.
18. Hayashi I, Mosher DF. Purification of stabilised native vitronectin. In: Preissner KT, Rosenblatt S, Kost C, Wegerhoff J, Mosher D. eds. Biology of vitronectins and their receptors. Amsterdam: Elsevier. 1993; 13 20.
19. Korc-Grodzicki B, Chain D, Kreizman T, Shaltiel S. An enzymatic assay for vitronectin based on its selective phosphorylation by protein kinase A. Anal Biochem 1990; 188:288 94.
20. Marchalonis JJ. An enzymic method for the trace iodination of immunoglobulins and other proteins. Biochem J 1969; 113:299 305.
21. McConahey PJ, Dixon FJ. A method of trace iodination of proteins for immunologie studies. Int Areh Allergy 1966; 29:185 9.
22. Akama T, Yamada KM, Sero N, Matsumoto I, Koni I, Kashiwagi H, Fumaki T, Havashi M. Immunological characterisation of human vitronectin and its binding to glycosaminoglycans. J Biochem 1986; 100:1343 51.
23. Morris CA, Underwood PA, Bean PA, Sheehan M, Charlesworth JA. Relative topography of biologically active domains of human vitronectin. Evidence from monoclonal antibody epitope and denaturation studies. J Biol Chem. 1994; 269:23845 52.
24. Milis L, Morris CA, Sheehan MC, Charlesworth JA, Pussell BA. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Clin. Exp. Immunol. 1993; 92:114 9.
25. Stockmann A, Hess S, Declerck R, Timpl R, Preissner KT. Multimeric vitronectin. Identification and characterisation of conformation-dependent self-association of the adhesive protein. J Biol Chem. 1993; 268:22874 82.
26. Charlesworth JA, Timmermans V, Golding J, Campbell LV, Peake P, Pussell BA, Wakefield D, Howard N. The complement system in type 1 (insulin-dependent) diabetes. Diabetologia 1987; 30:372 9.
27. Pussell BA, Peake PW, Brown MA, Charlesworth JA. Human fibronectin metabolism. J Clin Invest 1985; 76:143 8.
28. Chain D, Korc-Grodzicki B, Kreizman T, Shaltiel S. The phosphorylation of the two-chain form of vitronectin by protein kinase A is heparin dependent. FEBS Lett. 1990; 269:221 5.
29. Bhakdi S-., Hugo F, Tranum-Jensen J. Functions and relevance of the terminal complement sequence. Blut 1990; 60:309-18.
30. Sheehan M, Morris, CA, Pussell, BA. Charlesworth JA. Complement inhibition by human vitronectin involves non-heparin binding domains. Clin Exp Immunol 1995; 101:136 41.